SEC Form 4 · accession 0001203311-17-000096

SEATTLE GENETICS INC /WA · SGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

Dec 4, 2017

Accepted (ET)

Dec 6, 2017 · 8:04 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001060736

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Dec 4, 2017	M	3,729	$26.10	A	121,153	D
Common Stock^F2,F1	Dec 4, 2017	S	3,729	$58.7535	D	117,424	D
Common Stock^F1	Dec 4, 2017	M	2,436	$41.04	A	119,860	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option (right to buy)^F3	$41.04	Dec 4, 2017	M	2,436	D	—	Aug 19, 2023	Common Stock	2,436	0	D
Non-Qualified Stock Option (right to buy)^F4	$26.10	Dec 4, 2017	M	3,729	D	—	Aug 20, 2022	Common Stock	3,729	24,700	D

F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2Reflects sales of common stock executed in multiple transactions at prices ranging from $58.53 to $58.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3Shares vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17.
F4Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16.